SunWay Biotech Co Ltd

SunWay Biotech maintains a strong liquidity position with a current ratio of 3.69, indicating the ability to cover short-term obligations. The company's liquidity FPT (free cash flow to total debt) is positive, supported by operating cash flow of TWD 156.9 million and free cash flow of TWD 19.1 million. However, net cash is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity (ROE) of 3.63% and return on assets (ROA) of 3.13%, both below the industry median for Food Processing. The company's gross margin is 56.2% (TWD 545.0 million gross profit on TWD 970.2 million revenue), but operating margin is 14.5%, reflecting high operating expenses. Net income of TWD 118.6 million represents a 12.2% margin, which is in line with the sector but not exceptional. The company operates in a single business segment focused on health foods, with revenue concentrated in domestic and overseas markets. No specific geographic breakdown is provided, but the company's operations are primarily in Taiwan. This concentration may expose the company to regional economic and regulatory risks. SunWay Biotech's revenue growth is modest, with no significant changes in the current fiscal year. The company's outlook for the next fiscal year is neutral, with no projected revenue growth. Capital expenditures were negative at TWD -123.7 million, suggesting asset disposals or reduced investment in physical infrastructure. Risk factors include a medium liquidity risk due to the negative net cash position and a low dilution risk, as shares outstanding have not changed between basic and diluted. The company has not disclosed any recent equity issuance or dilutive events. Adjustments to valuations have not been applied, indicating no material changes in capital structure or earnings. Recent filings and transcripts do not highlight any material events or strategic shifts. The company continues to focus on its core health food products and markets. No significant R&D or expansion projects were disclosed in the latest financial statements.